

KEY FACTS

CREATION: 2003

PRIVATE FINANCING: €96M

TEAM

Mr. Francesco Micheli

Chairman, co-founder

Mr. Lorenzo Tallarigo, MD

Chief Executive Officer

Mr. Paolo Fundarò

Chief Financial Officer

Dr Federica Draghi, PhD MBA

Director, Business development

GENEXTRA S.p.A.

Via Giovannino De Grassi, 11

20123 Milano

T +390236515110

F +390236515115

info@genextra.it

MISSION

Genextra is a group of companies in the biotechnology sector committed to generating value by promoting the development of academic and clinical innovative tools.

BUSINESS STRATEGY

Genextra develops its programs through four subsidiaries: Congenia, DAC, Tethis and Intercept Pharmaceuticals. The efficiency and flexibility of Genextra's unique business model and holding structure is specifically designed to encourage and facilitate partnering efforts at any stage of drug development.

R&D PROGRAMS

TARGETING BILE ACID RECEPTOR – INTERCEPT PHARMACEUTICALS

Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases. The company's current drug development programs are focused on modulating bile acid receptors with an initial focus on amelioration of metabolic and hepatic function in chronic liver diseases. Intercept's lead candidate is an FXR agonist currently completing phase II for the treatment of Primary Biliary Cirrhosis and NASH.

MPTP- TARGETING MITOCHONDRIA - CONGENIA

Congenia is a biopharmaceutical company focused on the discovery and development of proprietary small-molecule product candidates that target mitochondrial oxidative stress-induced processes that lead to cell death.

HDAC AND HSP90 INHIBITORS- DAC

DAC is developing novel HDAC and HSP90 inhibitors for the treatment of cancer.

Currently, the most advanced compound is in Phase I/II for Non Melanoma Skin Cancers. In parallel, DAC is further investigating other compounds for their potential in solid and haematological cancers.

PMCS FOR NANOSTRUCTURED FILMS - TETHIS

The technologies at the basis of Tethis' activity allow the precise production and manipulation of nanoparticles in gas phase to yield either the synthesis of nanoparticles by flame spray pyrolysis (FSP) or the deposition of nanostructured thin films applying supersonic cluster beams (SCBD).

These unique innovative materials and revolutionary coating solutions find application in a broad range of sectors; currently the two main areas of the company's interest are biotechnology and gas sensing.

GENEXTRA'S COMBINED PIPELINE

